-
-
-
-
-
-
-
Leerink Partners Starts I-Mab (IMAB) at Outperform
-
-
-
-
-
-
-
I-Mab acquires Bridge Health to strengthen givastomig IP rights
-
-
-
-
-
-
-
Lucid Capital Markets Starts I-Mab (IMAB) at Buy
-
-
-
-
-
-
-
I-Mab Biopharma (IMAB) Presents Updated Phase 1 Givastomig Data at ESMO 2024
-
-
-
-
408,687 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

